triple acting glp 1 GLP-1-based therapies for type 2 diabetes: from single, dual and agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome Naturally optimize your appetite A review of an investigational

[PMCID:PMC11043712]

If symptoms persist or worsen it is important to discuss with your healthcare provider as you may benefit from reducing your current dose or trying an alternative medication

Restrain/Challenge Lack of Standardization and Clear Definition of GLP-1 Friendly Products The primary barrier to the growth of the GLP-1 friendly packaged food & beverage market is the lack of a defined concept of what constitutes "GLP-1 friendly." The phrase lacks a universal definition and has a lot of marketing behind it

Encourage patients to: Monitor portion sizes: Smaller portions can make a big difference in calorie intake

The plan is to offer patients a "long-term extension period" for their trials, giving whoever receives the placebo a chance to then switch and take the experimental drug